ATE132897T1 - Herpes simplex virus typ 1 mutante - Google Patents

Herpes simplex virus typ 1 mutante

Info

Publication number
ATE132897T1
ATE132897T1 AT90913020T AT90913020T ATE132897T1 AT E132897 T1 ATE132897 T1 AT E132897T1 AT 90913020 T AT90913020 T AT 90913020T AT 90913020 T AT90913020 T AT 90913020T AT E132897 T1 ATE132897 T1 AT E132897T1
Authority
AT
Austria
Prior art keywords
gene
hsv
base pairs
therapeutic gene
vivo
Prior art date
Application number
AT90913020T
Other languages
English (en)
Inventor
Christopher Maurice Preston
Christopher Ian Ace
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Application granted granted Critical
Publication of ATE132897T1 publication Critical patent/ATE132897T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90913020T 1989-08-15 1990-08-14 Herpes simplex virus typ 1 mutante ATE132897T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898918616A GB8918616D0 (en) 1989-08-15 1989-08-15 Herpes simplex virus type 1 mutant

Publications (1)

Publication Number Publication Date
ATE132897T1 true ATE132897T1 (de) 1996-01-15

Family

ID=10661668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90913020T ATE132897T1 (de) 1989-08-15 1990-08-14 Herpes simplex virus typ 1 mutante

Country Status (12)

Country Link
US (1) US5837532A (de)
EP (1) EP0487611B1 (de)
JP (1) JP3000482B2 (de)
AT (1) ATE132897T1 (de)
AU (1) AU628650B2 (de)
CA (1) CA2067330C (de)
DE (1) DE69024809T2 (de)
DK (1) DK0487611T3 (de)
ES (1) ES2084703T3 (de)
GB (2) GB8918616D0 (de)
WO (1) WO1991002788A1 (de)
ZA (1) ZA906401B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5688936A (en) * 1992-06-11 1997-11-18 The Regents Of The University Of California Vesicle membrane transport proteins
CA2145535C (en) * 1992-09-25 2007-07-17 Axel Kahn Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
GB9415319D0 (en) * 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
EP0856062A2 (de) * 1995-10-19 1998-08-05 St. Jude Children's Research Hospital Herpesvirus-vektoren und deren verwendung
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
BR9806741A (pt) * 1997-02-14 2000-02-29 Binney & Smith Inc Composição para coloração lavável
US5981626A (en) * 1997-02-14 1999-11-09 Binney & Smith Inc. Washable coloring composition suitable for use in dry erase markers
US5900094A (en) * 1997-02-14 1999-05-04 Binney & Smith Inc. Image transfer method for use with water based dry erase markers
GB9807865D0 (en) * 1998-04-09 1998-06-10 Univ London Herpes simplex virus latency associated transcript polypeptides
ES2539941T3 (es) * 2001-05-09 2015-07-07 Takara Bio, Inc. Composición y método para tratar el cáncer usando herpes virus
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US9023617B2 (en) * 2004-02-17 2015-05-05 University Of Florida Research Foundation, Inc. Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
EP1805213B1 (de) 2004-10-28 2015-11-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Peripher verabreichte gentherapie mit glutaminsäure-decarboxylase gegen schmerzen aufgrund einer rückenmarksverletzung
US7825231B2 (en) 2005-06-01 2010-11-02 Darren P. Wolfe Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
US20060275812A1 (en) * 2005-06-01 2006-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Assay for agonists and antagonists of ion channels and for regulators of genetic expression
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
CA2663109A1 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsylvania Hsv-1 and hsv-2 vaccines and methods of use thereof
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US20080289058A1 (en) 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
CN103038343A (zh) 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012122025A2 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
WO2016037161A2 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
AR107469A1 (es) 2016-01-27 2018-05-02 Oncorus Inc Vectores virales oncolíticos y sus usos
CN109311963A (zh) 2016-04-14 2019-02-05 蓝鸟生物公司 救助嵌合抗原受体系统
US10821140B2 (en) * 2016-04-22 2020-11-03 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3500696A4 (de) 2016-08-16 2020-04-08 Bluebird Bio, Inc. Il-10-rezeptor-alpha-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
MA46059A (fr) 2016-08-23 2019-07-03 Bluebird Bio Inc Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
ES2952525T3 (es) 2016-09-08 2023-11-02 2Seventy Bio Inc Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
EP3526334A4 (de) 2016-10-17 2020-09-30 Bluebird Bio, Inc. Tgfbetar2-homing-endonukleasevarianten, zusammensetzungen und verfahren zur verwendung
IL309526B2 (en) 2016-11-17 2025-02-01 2Seventy Bio Inc TGFBeta signal converter
MX2019008143A (es) 2017-01-07 2020-01-13 Selecta Biosciences Inc Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos.
ES2969213T3 (es) 2017-02-15 2024-05-17 2Seventy Bio Inc Plantillas de reparación de donantes para edición multiplex del genoma
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
KR102742817B1 (ko) 2017-05-25 2024-12-17 리제너론 파마슈티칼스 인코포레이티드 Cblb 엔도뉴클레아제 변이체, 조성물 및 사용 방법
CN111433358B (zh) 2017-07-13 2024-04-30 迈阿密大学 用于管理疼痛的方法
EP3658165A4 (de) 2017-07-26 2021-09-01 Oncorus, Inc. Onkolytische virusvektoren und verwendungen davon
EP3687561A4 (de) 2017-09-01 2021-06-09 The Australian National University Immunregulatorische moleküle und deren verwendung
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
WO2019070974A1 (en) 2017-10-04 2019-04-11 Bluebird Bio, Inc. PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US12178908B2 (en) 2018-02-26 2024-12-31 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
US12060419B2 (en) 2018-06-14 2024-08-13 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
AU2019395334A1 (en) 2018-12-10 2021-06-24 Regeneron Pharmaceuticals, Inc. PDCD-1 homing endonuclease variants
US12404500B2 (en) 2018-12-10 2025-09-02 Novo Nordisk A/S Homing endonuclease variants
CN113366479A (zh) 2018-12-14 2021-09-07 蓝鸟生物公司 二聚化剂调节的免疫受体复合物
CN114072517A (zh) * 2019-03-14 2022-02-18 麻省理工学院 工程化的单纯疱疹病毒-1(hsv-1)载体及其用途
WO2020223205A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
WO2020243261A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
AU2020364144A1 (en) 2019-10-10 2022-05-26 Virogin Biotech Canada Ltd Dual viruses and dual oncolytic viruses and methods of treatment
JP7769388B2 (ja) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
US20230226223A1 (en) 2020-04-10 2023-07-20 Sola Biosciences Llc Compositions and Methods for the Treatment of Protein Aggregation Disorders
AU2021265088A1 (en) 2020-04-28 2022-11-03 Sola Biosciences Llc Compositions and methods for the treatment of TDP-43 proteinopathies
CA3183251A1 (en) 2020-06-05 2021-12-09 Sola Biosciences Llc Compositions and methods for the treatment of synucleinopathies
EP4162036A1 (de) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Lösliche enpp1- oder enpp3-proteine und verwendungen davon
CN111635913B (zh) * 2020-06-16 2022-03-04 广东东阳光药业有限公司 构建体及其应用
TW202233655A (zh) 2020-10-26 2022-09-01 美商碩拿生物科學有限責任公司 用於治療阿茲海默症之組合物及方法
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
EP4413023A1 (de) 2021-10-08 2024-08-14 SOLA Biosciences LLC Zusammensetzungen und verfahren zur behandlung von p53-vermitteltem krebs
US20250042958A1 (en) 2021-10-08 2025-02-06 Sola Biosciences Llc Compositions and methods for the treatment of proteopathies
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
CN119546327A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
CN120882864A (zh) 2022-09-30 2025-10-31 国立大学法人 东京大学 靶向il13ra2的单纯疱疹病毒及抗il13ra2抗体或其抗原结合片段
WO2025153530A1 (en) 2024-01-16 2025-07-24 Novo Nordisk A/S Albumin-targeted endonucleases, compositions, and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
EP0349598A1 (de) * 1987-03-13 1990-01-10 Schering Corporation Verfahren zur stimulierung der gen-expression
CA2045129A1 (en) * 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication

Also Published As

Publication number Publication date
CA2067330C (en) 2005-05-10
GB9017767D0 (en) 1990-09-26
ZA906401B (en) 1991-06-26
AU628650B2 (en) 1992-09-17
GB8918616D0 (en) 1989-09-27
DE69024809T2 (de) 1996-05-30
JPH05505302A (ja) 1993-08-12
AU6276290A (en) 1991-04-03
GB2234972B (en) 1993-08-04
DK0487611T3 (da) 1996-05-20
CA2067330A1 (en) 1991-02-16
ES2084703T3 (es) 1996-05-16
DE69024809D1 (de) 1996-02-22
GB2234972A (en) 1991-02-20
EP0487611A1 (de) 1992-06-03
WO1991002788A1 (en) 1991-03-07
JP3000482B2 (ja) 2000-01-17
EP0487611B1 (de) 1996-01-10
US5837532A (en) 1998-11-17

Similar Documents

Publication Publication Date Title
ATE132897T1 (de) Herpes simplex virus typ 1 mutante
Smith et al. Antiviral effect of an oligo (nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.
Caradonna et al. Induction of uracil-DNA glycosylase and dUTP nucleotidohydrolase activity in herpes simplex virus-infected human cells.
Khoury et al. Enhancer elements
Morgan et al. Identification of the DNA sequences encoding the large subunit of the mRNA-capping enzyme of vaccinia virus
ATE141517T1 (de) Gen-sequenzentransfer und -exprimierung bei zellen des zentralen nervensystems mit mutierenden herpes-simplex-viren, die deletionen in viren-replikationsgenen enthalten
Protić et al. Enhancement of DNA repair capacity of mammalian cells by carcinogen treatment
CA2011654A1 (en) Recombinant poxvirus host range selection system
JPWO2020081568A5 (de)
ATE113077T1 (de) Stabile integration von dna in bakterielle genome.
AUPN477695A0 (en) Gene therapy
ATE73348T1 (de) Thymidinkinase-deletionsmutanten von bovinem herpesvirus-1, diese enthaltende impfstoffe gegen bovine rhinotracheitis und verfahren zu deren herstellung und verwendung.
Spang et al. Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein
Keller et al. Role of the human cytomegalovirus major immediate-early promoter's 19-base-pair-repeat cyclic AMP-response element in acutely infected cells
Deb et al. A 67-base-pair segment from the Ori-S region of herpes simplex virus type 1 encodes origin function
Vasseur et al. Physical and biological features of polyoma virus mutants able to infect embryonal carcinoma cell lines
EP0326127A3 (de) Infektiöse Rinder-Rhinotracheitis-Virus-Insertionsmutanten, sie enthaltende Impfstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung
Cole et al. Biological properties of simian virus 40 host range mutants lacking the COOH-terminus of large T antigen
Hall et al. Structural organization and unusual codon usage in the DNA polymerase gene from herpes simplex virus type 1
ATE164885T1 (de) Abgeschwächte herpesviren, herpesviren, die eine für aminosäuresequenzen kodierende fremd-dns enthalten, sowie impfstoffe, die diese enthalten
BR9912719A (pt) Processo para propagar um vìrus do herpes mutante, uso de uma linhagem de célula, linhagem de célula, vìrus, e, composição farmacêutica
ATE454453T1 (de) Virale nukleotidsequenzen
Pedrali-Noy et al. Evidence of a repetitive sequence in vaccinia virus DNA
Tseng et al. Multiple domains in the polyomavirus B enhancer are required for productive infection of F9 embryonal carcinoma cells
Robertson Oncogenes and the origins of human cancer

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee